|Day Low/High||7.60 / 7.97|
|52 Wk Low/High||4.10 / 15.02|
A report released by Missouri Sen. Claire McCaskill points to $10 million of payments flowing from a group of five opioid-producing companies to 15 patient advocacy groups over a five-year period.
Investors in Insys Therapeutics Inc saw new options become available this week, for the March 16th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the INSY options chain for the new March 16th contracts and identified one put and one call contract of particular interest.
In recent trading, shares of Insys Therapeutics Inc have crossed above the average analyst 12-month target price of $12.75, changing hands for $13.38/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.
Here's a look at biotech stock trades, takeout targets and pot sellers that will dominate 2018.
Consumers in California eagerly await the end to it prohibition on the recreational use of cannabis.
Investors in Insys Therapeutics Inc saw new options become available this week, for the August 2018 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 240 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.
Proof-of-concept study aims to assess efficacy, safety, tolerability and pharmacokinetics of company's novel CBD product candidate
Using standard intramuscular injection as comparator, company's Phase 1 clinical trial enrolls first patient
Novel formulation of partial opioid offers potential benefits compared to current alternatives
Investors in Insys Therapeutics Inc saw new options become available this week, for the January 2018 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the INSY options chain for the new January 2018 contracts and identified one put and one call contract of particular interest.
Official Launch of SYNDROS® and Filing NDA for Buprenorphine Sublingual Spray Drive Progress on Strategic Initiatives
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Insys Therapeutics, Inc.
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.
Investors eyeing a purchase of Insys Therapeutics Inc shares, but cautious about paying the going market price of $7.37/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the February 2018 put at the $6 strike, which has a bid at the time of this writing of 45 cents.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.